News

/
/
PTRCR19 – REGN-COV2 for the treatment of COVID-19 Rapid Collaborative Review- Final Rapid Collaborative Review now available.

PTRCR19 – REGN-COV2 for the treatment of COVID-19 Rapid Collaborative Review- Final Rapid Collaborative Review now available.

This is the third pharmaceutical Rapid Collaborative Review (PTRCR19) published by EUnetHTA. This report describes REGN-COV2 for the treatment of COVID-19 patients.

In March 2021, after an Article 5(3) review the European Medicines Agency (EMA) endorsed the use of REGN-COV2 for the treatment of confirmed COVID-19 in patients aged 12 years and older that do not require supplemental oxygen for COVID-19 and who are at high risk of progressing to severe COVID-19. The EUnetHTA Rapid Collaborative Review aims to define, according to the national requirements of the EUnetHTA partners, the PICO, an overview of available evidence and Evidence gaps of REGN-COV2 in the target patient populations with relevant comparators.

For any questions regarding the Rapid Collaborative Review, please contact eunethta@zinl.nl.

Please find the review here:

PTRCR19 – Final Rapid Collaborative Review 

This website uses cookies to ensure you get the best experience on our website. By using the website you agree to our Privacy Policy and our Terms of Use.